M. Raheel Khan, Consultant Medical Oncologist at St James’s Hospital, Dublin, Research Registrar in Oncology at Tallaght University Hospital and Lead Investigator at Cancer Trials Ireland, shared a post on X:
“Ultra-low doses of Nivolumab showed promising efficacy in recently published DELLI trial.
Here we discuss the application of this study in a wider population.
Read the full article on JCO.”
Title: How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability
Authors: M. Raheel Khan, Patrick M. Forde
Other articles on Nivolumab on OncoDaily.